Acelyrinincis A Late Stage Clinical Biopharmaceutical Company Based In Agoura Hillscaliforniawith Additional Operations In Los Angeles And The San Francisco Bay Areafounded In 2020The Company Is Publicly Traded On Nasdaq Under The Ticker Slrnacelyrin Focuses On Developing And Commercializing Transformative Therapiesparticularly In The Field Of Immunology The Company Employs 83 Staff And Is Led By Ceo Mina Kimacelyrin Emphasizes Acourageous Caringethosaiming To Deliver Clinically Meaningful Treatments With Urgencyits Business Model Includes Identifying And Acquiring Promising Therapeutic Programsimplementing Accelerated Development Strategiesand Engaging In Partnerships To Expand Its Portfoliothe Lead Candidatelonigutamabis A Monoclonal Antibody Targeting Igf 1Rwhich Has Completed Phase 2 Trials For Thyroid Eye Diseaseacelyrin Is Committed To Addressing Unmet Medical Needs For Patients With Immunological Disorders Through Its Innovative Therapies
